Appendix G - professional organisation submission template

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma after chemotherapy [ID741]

Thank you for agreeing to make a submission on your organisation's view of the technology and the way it should be used in the NHS.

Healthcare professionals can provide a unique perspective on the technology within the context of current clinical practice which is not typically available from the published literature.

To help you in making your submission, we have provided a template. The questions are there as prompts to guide you. It is not essential that you answer all of them.

Please do not exceed the 8-page limit.

About you

Your name:

Name of your organisation: The Royal College of Radiologists
Are you (tick all that apply):

- a specialist in the treatment of people with the condition for which NICE is considering this technology? Yes

- a specialist in the clinical evidence base that is to support the technology (e.g. involved in clinical trials for the technology)? Yes

- an employee of a healthcare professional organisation that represents clinicians treating the condition for which NICE is considering the technology? If so, what is your position in the organisation where appropriate (e.g. policy officer, trustee, member etc)? Yes

- other? (please specify)

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma after chemotherapy [ID741]

What is the expected place of the technology in current practice?

How is the condition currently treated in the NHS? Is there significant geographical variation in current practice? Are there differences of opinion between professionals as to what current practice should be? What are the current alternatives (if any) to the technology, and what are their respective advantages and disadvantages?
25-30% of people with advanced oesophago-gastric adenocarcinoma will be eligible to receive 2nd line palliative chemotherapy following initial response to 1st line platinum combination. In addition another 20-30% will be suitable to receive second line treatment who do not respond to platinum based chemotherapy. Nearly half of the initial responders will be rechallenged with a platinum combination. The remaining half is poorly served as there is limited option in the form of different cytotoxic agents with poor efficacy.
Are there any subgroups of patients with the condition who have a different prognosis from the typical patient? Are there differences in the capacity of different subgroups to benefit from or to be put at risk by the technology?
Patients who do not respond to 1st line chemotherapy have a poorer prognosis and have very limited 2nd line treatment options.

In what setting should/could the technology be used – for example, primary or secondary care, specialist clinics? Would there be any requirements for additional professional input (for example, community care, specialist nursing, other healthcare professionals)?
The treatment would be delivered within oncology units specialising in delivering cytotoxic chemotherapy.

If the technology is already available, is there variation in how it is being used in the NHS? Is it always used within its licensed indications? If not, under what circumstances does this occur?
It is currently not available for routine use in NHS. An individual funding request could however be made to the Cancer Drugs Fund for appropriate patients.
Please tell us about any relevant **clinical guidelines** and comment on the appropriateness of the methodology used in developing the guideline and the specific evidence that underpinned the various recommendations.
Between RAINBOW and REGARD trials 1020 patients were assessed for the efficacy of Ramicirumab either in combination with weekly paclitaxel or as a single agent therapy. Both trials have shown a significant improvement in OS and PFS. Of particular interest is the doubling of PFS at 6 and 9 months when used in combination with Paclitaxel.

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma after chemotherapy [ID741]

The advantages and disadvantages of the technology

NICE is particularly interested in your views on how the technology, when it becomes available, will compare with current alternatives used in the UK. Will the technology be easier or more difficult to use, and are there any practical implications (for example, concomitant treatments, other additional clinical requirements, patient acceptability/ease of use or the need for additional tests) surrounding its future use?
This is a new standard of care in this setting. It will however need resourcing for clinic time, chemotherapy chair time and health-care facilities utilisation in order to deal with adverse effects of the treatment.

If appropriate, please give your view on the nature of any rules, informal or formal, for starting and stopping the use of the technology; this might include any requirements for additional testing to identify appropriate subgroups for treatment or to assess response and the potential for discontinuation.
Treatment with either single agent Ramicirumab or in combination with Paclitaxel should only be started in patients with WHO performance status of 0 or 1. Clinical and radiological assements will determine the efficacy and inform the stopping criteria.

If you are familiar with the evidence base for the technology, please comment on whether the use of the technology under clinical trial conditions reflects that observed in clinical practice. Do the circumstances in which the trials were conducted reflect current UK practice, and if not, how could the results be extrapolated to a UK setting? What, in your view, are the most important outcomes, and were they measured in the trials? If surrogate measures of outcome were used, do they adequately predict long-term outcomes?
The trial data is applicable to UK population and the encouraging fact is the maintanence of global quality of life between the treatment arms despite higher but manageable toxicity of the Ramicirumab containing arms.

What is the relative significance of any side effects or adverse reactions? In what ways do these affect the management of the condition and the patient's quality of life? Are there any adverse effects that were not apparent in clinical trials but have come to light subsequently during routine clinical practice?
Ramicirumab as single agent and in combination is more toxic but the side-effects are manageable and did not translate to a deterioration in QOL according to results published to date. However, further QOL data is expected from both trials.

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma after chemotherapy [ID741]

Any additional sources of evidence

Can you provide information about any relevant evidence that might not be found by a technology-focused systematic review of the available trial evidence? This could be information on recent and informal unpublished evidence, or information from registries and other nationally coordinated clinical audits. Any such information must include sufficient detail to allow a judgement to be made as to the quality of the evidence and to allow potential sources of bias to be determined.

NA

Implementation issues

The NHS is required by the Department of Health to provide funding and resources for medicines and treatments that have been recommended by NICE technology appraisal guidance. This provision has to be made within 3 months from the date of publication of the guidance.

If the technology is unlikely to be available in sufficient quantity, or the staff and facilities to fulfil the general nature of the guidance cannot be put in place within 3 months, NICE may advise the Department of Health to vary this direction.

Please note that NICE cannot suggest such a variation on the basis of budgetary constraints alone.

How would possible NICE guidance on this technology affect the delivery of care for patients with this condition? Would NHS staff need extra education and training? Would any additional resources be required (for example, facilities or equipment)? **Will affect pharmacy manufacturing time, chemotherapy chair time and clinic time.**

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma after chemotherapy [ID741]

Equality
NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. Please let us know if you think that this appraisal:

- could exclude from full consideration any people protected by the equality legislation who fall within the patient population for which [the treatment(s)] is/are/will be licensed;
- could lead to recommendations that have a different impact on people protected by the equality legislation than on the wider population, e.g. by making it more difficult in practice for a specific group to access the technology;
- could lead to recommendations that have any adverse impact on people with a particular disability or disabilities.

NA
Please tell us what evidence should be obtained to enable the Committee to identify and consider such impacts.
NA